Gilead Sciences' Trodelvy has met its objectives in a phase 2b trial in triple-negative breast cancer (TNBC) carried out in China by its partner Everest Medicines, moving it closer to a regulatory ...

Top of the list are recent disappointments in clinical trials for TROP2-directed antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan), which was the crown jewel in Gilead's $21 billion ...